Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France Nicolas.

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort Michèle Beau-Faller, MD,

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France Nicolas.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers Christos.

ALK FISH and IHC: You Cannot Have One without the Other

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Nicolas Guibert,

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer Eiko Theodora Browning, MD, Andrew James.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors.

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma Nader Abedallaa, MD, Lise Tremblay, MD, Charlotte.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin- Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer:

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based.

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Characteristics of Thoracic Malignancies That Occur After Solid-Organ Transplantation Caroline Génébès, MD, Laurent Brouchet, MD, PhD, Nassim Kamar, MD,

Specificities of Lung Adenocarcinoma in Women Who Have Never Smoked

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

S768I Mutation in EGFR in Patients with Lung Cancer

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

Journal of Thoracic Oncology

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for.

Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France Nicolas Guibert, MD, Fabrice Barlesi, MD, PhD, Renaud Descourt, MD, Hervé Léna, MD, Benjamin Besse, MD, PhD, Michèle Beau- Faller, MD, PhD, Jean Mosser, MD, PhD, Eric Pichon, MD, Jean-Philippe Merlio, MD, PhD, L'Houcine Ouafik, MD, PhD, François Guichard, MD, Bénédicte Mastroianni, MD, Lionel Moreau, MD, Annie Wdowik, MD, Jean-Christophe Sabourin, MD, Antoinette Lemoine, MD, PhD, Pascale Missy, PhD, Alexandra Langlais, MSc, Denis Moro-Sibilot, MD, PhD, Julien Mazières, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 6, Pages 963-973 (June 2017) DOI: 10.1016/j.jtho.2017.02.001 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Overall survival (OS) in the presence of double mutation involving EGFR compared to EGFR mutated patients. (A) OS in patients harboring double mutation involving EGFR (EGFR+X) compared to EGFR mutated patients. (B) OS in the presence of EGFR and PI3K co-mutation compared to EGFR mutated patients. (C) OS in the presence of EGFR and ALK co-mutation compared to EGFR mutated patients. (D) OS in the presence of EGFR and KRAS co-mutation compared to EGFR mutated patients. IC95%, concentration that inhibits 95%; HR, hazard ratio; NR, not reached. Journal of Thoracic Oncology 2017 12, 963-973DOI: (10.1016/j.jtho.2017.02.001) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Progression-free survival (PFS) in the presence of double mutation involving EGFR compared to EGFR mutated patients. (A) PFS in the whole population of patients harboring double mutation involving EGFR (EGFR+X) compared to EGFR mutated patients. (B) PFS in the presence of EGFR and PI3K co-mutation compared to EGFR mutated patients. (C) PFS in the presence of EGFR and ALK co-mutation compared to EGFR mutated patients. (D) PFS in the presence of EGFR and KRAS co-mutation compared to EGFR mutated patients. Journal of Thoracic Oncology 2017 12, 963-973DOI: (10.1016/j.jtho.2017.02.001) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Response to targeted therapies in the presence of a double mutation compared to a single mutation. (A) Response to first-line treatment by EGFR-TKIs in patients harboring double mutation involving EGFR (EGFR+X) compared to EGFR mutated patients. (B) Response to second-line treatment by EGFR-TKIs in patients harboring double mutation involving EGFR (EGFR+X) compared to EGFR mutated patients. (C) Response to EGFR-TKIs in the presence of EGFR and PI3K co-mutation compared to EGFR mutated patients. (D) Response to crizotinib in patients harboring double molecular alterations involving ALK rearrangement (ALK+X) compared to ALK patients. Journal of Thoracic Oncology 2017 12, 963-973DOI: (10.1016/j.jtho.2017.02.001) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Response to chemotherapy in the presence of a double mutation including KRAS compared to KRAS mutated patients. (A) Response to chemotherapy in patients harboring double mutation involving KRAS (KRAS+X) compared to KRAS mutated patients. (B) Response to chemotherapy in the presence of KRAS and EGFR co-mutation compared to KRAS mutated patients. (C) Response to chemotherapy in the presence of KRAS mutation and ALK rearrangement compared to KRAS mutated patients. (D) Response to chemotherapy in the presence of KRAS and PI3K co-mutation compared to KRAS mutated patients. Journal of Thoracic Oncology 2017 12, 963-973DOI: (10.1016/j.jtho.2017.02.001) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions